Johnson & Johnson successfully completes acquisition of Ambrx Biopharma, Inc. to enhance oncology therapeutics
Mar 07, 2024•almost 2 years ago
Acquiring Company
Johnson & Johnson
Acquired Company
Ambrx
San DiegoBiopharmaTherapeuticsBiotechnologyHealth CareDescription
Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company known for its proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs). This strategic acquisition reinforces Johnson & Johnson's commitment to advancing precision biologics and transforming the treatment of cancers, including prostate cancer.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed